Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience Pierpaolo CorrealeMaria Grazia CusiGiorgio Giorgi OriginalPaper 24 February 2006 Pages: 99 - 110
Novel in vitro model barriers for evaluation of the permeability of antitumor compounds, thioxanthones Venugopal MarasanapalleXiaoling LiBhaskara R. Jasti OriginalPaper 24 February 2006 Pages: 111 - 116
Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies Cheryl D. ChoGeorge A. FisherBranimir I. Sikic OriginalPaper 20 July 2005 Pages: 117 - 123
A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers Sanjay GoelKavita DesaiSridhar Mani OriginalPaper 20 July 2005 Pages: 125 - 134
Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma Elisabeth I. HeathBarbara A. BurtnessArlene A. Forastiere Short Report 24 February 2006 Pages: 135 - 140
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma Amy C. PetersonHelena HarlinWalter M. Stadler OriginalPaper 28 February 2006 Pages: 141 - 149
Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial Toshiyuki SawaTakashi YanaYutaka Ariyoshi OriginalPaper 24 February 2006 Pages: 151 - 158
Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study Eric WinquistJennifer KnoxElizabeth Eisenhauer OriginalPaper 24 February 2006 Pages: 159 - 167
